Skip to main content
Top
Published in: Aesthetic Plastic Surgery 5/2018

01-10-2018 | Original Article

A Randomized, Placebo-Controlled, Double-Blind, Prospective Clinical Trial of Botulinum Toxin Type A in Prevention of Hypertrophic Scar Development in Median Sternotomy Wound

Authors: Yue-Hua Li, Jiaomei Yang, Jia-Qi Liu, Song-Tao Xie, Yi-Jie Zhang, Wei Zhang, Ju-Lei Zhang, Zhao Zheng, Da-Hai Hu

Published in: Aesthetic Plastic Surgery | Issue 5/2018

Login to get access

Abstract

Background

Linear hypertrophic scar is a common surgical problem that can be difficult to manage, especially for the median sternotomy scar. Botulinum toxin type A (BTA) is widely used in cosmetic surgery and has been shown to improve scar quality recently. The aim of this study was to evaluate the efficacy of BTA injected in the early postoperative of median sternotomy on preventing scar formation.

Methods

In this prospective randomized controlled trial, 19 consecutive patients who underwent median sternotomy were enrolled. The median sternotomy wound in each patient was divided into the upper half and the lower half. Both halves of the wound were randomized to receive the treatment with either BTA or normal saline. At 6-month follow-up, scars were assessed using the Vancouver Scar Scale, scar widths were measured, and patients were asked to evaluate their overall satisfaction.

Results

Seventeen patients with median sternotomy wounds completed the entire study. At 6-month follow-up, the mean Vancouver Scar Scale score for the BTA-treated group was 3.44 ± 1.68 and for the normal saline control group was 6.29 ± 2.39, and there was a statistically significant difference between the two groups (P < 0.05). There were also significant improvements in scar width and patient satisfaction for the BTA-treated halves of the wounds (P < 0.05).

Conclusions

The study demonstrates that early postoperative BTA injection can decrease scar formation and reduce scar width in median sternotomy wounds, and the overall appearance is more satisfactory.

Level of Evidence I

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.​springer.​com/​00266.
Literature
1.
go back to reference Chan KY, Lau CL, Adeeb SM, Somasundaram S, Nasir-Zahari M (2005) A randomized, placebo-controlled, double-blind, prospective clinical trial of silicone gel in prevention of hypertrophic scar development in median sternotomy wound. Plast Reconstr Surg 116(4):1013–1020 (discussion 21–2) CrossRefPubMed Chan KY, Lau CL, Adeeb SM, Somasundaram S, Nasir-Zahari M (2005) A randomized, placebo-controlled, double-blind, prospective clinical trial of silicone gel in prevention of hypertrophic scar development in median sternotomy wound. Plast Reconstr Surg 116(4):1013–1020 (discussion 21–2) CrossRefPubMed
2.
go back to reference Sproat JE, Dalcin A, Weitauer N, Roberts RS (1992) Hypertrophic sternal scars: silicone gel sheet versus Kenalog injection treatment. Plast Reconstr Surg 90(6):988–992CrossRefPubMed Sproat JE, Dalcin A, Weitauer N, Roberts RS (1992) Hypertrophic sternal scars: silicone gel sheet versus Kenalog injection treatment. Plast Reconstr Surg 90(6):988–992CrossRefPubMed
3.
go back to reference Hallett M (1999) One man’s poison–clinical applications of botulinum toxin. N Engl J Med 341(2):118–120CrossRefPubMed Hallett M (1999) One man’s poison–clinical applications of botulinum toxin. N Engl J Med 341(2):118–120CrossRefPubMed
4.
go back to reference Pirazzini M, Rossetto O, Eleopra R, Montecucco C (2007) Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev 69(2):200–235CrossRef Pirazzini M, Rossetto O, Eleopra R, Montecucco C (2007) Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev 69(2):200–235CrossRef
5.
go back to reference Mehta M, Branford OA, Rolfe KJ (2016) The evidence for natural therapeutics as potential anti-scarring agents in burn-related scarring. Burns Trauma 4:15CrossRefPubMedPubMedCentral Mehta M, Branford OA, Rolfe KJ (2016) The evidence for natural therapeutics as potential anti-scarring agents in burn-related scarring. Burns Trauma 4:15CrossRefPubMedPubMedCentral
6.
go back to reference Young VL, Hutchison J (2009) Insights into patient and clinician concerns about scar appearance: semiquantitative structured surveys. Plast Reconstr Surg 124(1):256–265CrossRefPubMed Young VL, Hutchison J (2009) Insights into patient and clinician concerns about scar appearance: semiquantitative structured surveys. Plast Reconstr Surg 124(1):256–265CrossRefPubMed
8.
go back to reference Naumann M, Dressler D, Hallett M, Jankovic J, Schiavo G, Segal KR (2013) Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon Off J Int Soc Toxinol 67:141–152CrossRef Naumann M, Dressler D, Hallett M, Jankovic J, Schiavo G, Segal KR (2013) Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon Off J Int Soc Toxinol 67:141–152CrossRef
9.
go back to reference Lakraj AA, Moghimi N, Jabbari B (2013) Hyperhidrosis: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins 5(4):821–840CrossRefPubMedPubMedCentral Lakraj AA, Moghimi N, Jabbari B (2013) Hyperhidrosis: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins 5(4):821–840CrossRefPubMedPubMedCentral
10.
go back to reference O’Leary M, Dierich M (2010) Botulinum toxin type A for the treatment of urinary tract dysfunction in neurological disorders. Urol Nurs 30(4):228–234CrossRefPubMed O’Leary M, Dierich M (2010) Botulinum toxin type A for the treatment of urinary tract dysfunction in neurological disorders. Urol Nurs 30(4):228–234CrossRefPubMed
11.
go back to reference Gassner HG, Brissett AE, Otley CC, Boahene DK, Boggust AJ, Weaver AL (2006) Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. Mayo Clin Proc 81(8):1023–1028CrossRefPubMed Gassner HG, Brissett AE, Otley CC, Boahene DK, Boggust AJ, Weaver AL (2006) Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. Mayo Clin Proc 81(8):1023–1028CrossRefPubMed
12.
go back to reference Zhang DZ, Liu XY, Xiao WL, Xu YX (2016) Botulinum toxin type A and the prevention of hypertrophic scars on the maxillofacial area and neck: a meta-analysis of randomized controlled trials. PLoS ONE 11(3):e0151627CrossRefPubMedPubMedCentral Zhang DZ, Liu XY, Xiao WL, Xu YX (2016) Botulinum toxin type A and the prevention of hypertrophic scars on the maxillofacial area and neck: a meta-analysis of randomized controlled trials. PLoS ONE 11(3):e0151627CrossRefPubMedPubMedCentral
13.
go back to reference Chang CS, Wallace CG, Hsiao YC, Chang CJ, Chen PK (2014) Botulinum toxin to improve results in cleft lip repair. Plast Reconstr Surg 134(3):511–516CrossRefPubMed Chang CS, Wallace CG, Hsiao YC, Chang CJ, Chen PK (2014) Botulinum toxin to improve results in cleft lip repair. Plast Reconstr Surg 134(3):511–516CrossRefPubMed
14.
go back to reference Chang CS, Wallace CG, Hsiao YC, Chang CJ, Chen PK (2014) Botulinum toxin to improve results in cleft lip repair: a double-blinded, randomized, vehicle-controlled clinical trial. PLoS ONE 9(12):e115690CrossRefPubMedPubMedCentral Chang CS, Wallace CG, Hsiao YC, Chang CJ, Chen PK (2014) Botulinum toxin to improve results in cleft lip repair: a double-blinded, randomized, vehicle-controlled clinical trial. PLoS ONE 9(12):e115690CrossRefPubMedPubMedCentral
15.
go back to reference Ziade M, Domergue S, Batifol D, Jreige R, Sebbane M, Goudot P (2013) Use of botulinum toxin type A to improve treatment of facial wounds: a prospective randomised study. J Plast Reconstr Aesthet Surg 66(2):209–214CrossRefPubMed Ziade M, Domergue S, Batifol D, Jreige R, Sebbane M, Goudot P (2013) Use of botulinum toxin type A to improve treatment of facial wounds: a prospective randomised study. J Plast Reconstr Aesthet Surg 66(2):209–214CrossRefPubMed
16.
go back to reference Al-Qattan MM, Al-Shanawani BN, Alshomer F (2013) Botulinum toxin type A: implications in wound healing, facial cutaneous scarring, and cleft lip repair. Ann Saudi Med 33(5):482–488CrossRefPubMed Al-Qattan MM, Al-Shanawani BN, Alshomer F (2013) Botulinum toxin type A: implications in wound healing, facial cutaneous scarring, and cleft lip repair. Ann Saudi Med 33(5):482–488CrossRefPubMed
17.
go back to reference Xiao Z, Qu G (2012) Effects of botulinum toxin type a on collagen deposition in hypertrophic scars. Molecules 17(2):2169–2177CrossRefPubMed Xiao Z, Qu G (2012) Effects of botulinum toxin type a on collagen deposition in hypertrophic scars. Molecules 17(2):2169–2177CrossRefPubMed
18.
go back to reference Xiao Z, Zhang M, Liu Y, Ren L (2011) Botulinum toxin type a inhibits connective tissue growth factor expression in fibroblasts derived from hypertrophic scar. Aesthet Plast Surg 35(5):802–807CrossRef Xiao Z, Zhang M, Liu Y, Ren L (2011) Botulinum toxin type a inhibits connective tissue growth factor expression in fibroblasts derived from hypertrophic scar. Aesthet Plast Surg 35(5):802–807CrossRef
19.
go back to reference Xiao Z, Zhang F, Lin W, Zhang M, Liu Y (2010) Effect of botulinum toxin type A on transforming growth factor beta1 in fibroblasts derived from hypertrophic scar: a preliminary report. Aesthet Plast Surg 34(4):424–427CrossRef Xiao Z, Zhang F, Lin W, Zhang M, Liu Y (2010) Effect of botulinum toxin type A on transforming growth factor beta1 in fibroblasts derived from hypertrophic scar: a preliminary report. Aesthet Plast Surg 34(4):424–427CrossRef
20.
go back to reference Jeong HS, Lee BH, Sung HM, Park SY, Ahn DK, Jung MS (2015) Effect of botulinum toxin type A on differentiation of fibroblasts derived from scar tissue. Plast Reconstr Surg 136(2):171e–178eCrossRefPubMed Jeong HS, Lee BH, Sung HM, Park SY, Ahn DK, Jung MS (2015) Effect of botulinum toxin type A on differentiation of fibroblasts derived from scar tissue. Plast Reconstr Surg 136(2):171e–178eCrossRefPubMed
21.
go back to reference Kim YS, Lee HJ, Cho SH, Lee JD, Kim HS (2014) Early postoperative treatment of thyroidectomy scars using botulinum toxin: a split-scar, double-blind randomized controlled trial. Wound Repair Regen 22(5):605–612CrossRefPubMed Kim YS, Lee HJ, Cho SH, Lee JD, Kim HS (2014) Early postoperative treatment of thyroidectomy scars using botulinum toxin: a split-scar, double-blind randomized controlled trial. Wound Repair Regen 22(5):605–612CrossRefPubMed
22.
go back to reference Scott AB, Suzuki D (1988) Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord Off J Mov Disord Soc 3(4):333–335CrossRef Scott AB, Suzuki D (1988) Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord Off J Mov Disord Soc 3(4):333–335CrossRef
24.
go back to reference Ozog DM, Moy RL (2015) Discussing fractional carbon dioxide laser and other physical treatments for scar prevention with patients. JAMA Dermatol 151(8):815–816CrossRefPubMed Ozog DM, Moy RL (2015) Discussing fractional carbon dioxide laser and other physical treatments for scar prevention with patients. JAMA Dermatol 151(8):815–816CrossRefPubMed
Metadata
Title
A Randomized, Placebo-Controlled, Double-Blind, Prospective Clinical Trial of Botulinum Toxin Type A in Prevention of Hypertrophic Scar Development in Median Sternotomy Wound
Authors
Yue-Hua Li
Jiaomei Yang
Jia-Qi Liu
Song-Tao Xie
Yi-Jie Zhang
Wei Zhang
Ju-Lei Zhang
Zhao Zheng
Da-Hai Hu
Publication date
01-10-2018
Publisher
Springer US
Published in
Aesthetic Plastic Surgery / Issue 5/2018
Print ISSN: 0364-216X
Electronic ISSN: 1432-5241
DOI
https://doi.org/10.1007/s00266-018-1187-x

Other articles of this Issue 5/2018

Aesthetic Plastic Surgery 5/2018 Go to the issue